Healthcare

AMN Healthcare connects hospitals with nurses, physicians, and workforce-management tools. After a severe post-pandemic reset, the company still shows scale, strong client reach, and improving cash generation, making its recovery path worth closer analysis.

Aktis Oncology is building targeted radiopharmaceutical cancer treatments in a fast-developing part of oncology. The company combines a focused platform, rising R&D commitment, and low debt, with future progress hinging on clinical execution and proof of its approach.

Zymeworks is a cancer-focused biotech building antibody-based therapies and monetizing its science through partnerships. The company’s appeal centers on oncology pipeline progress, licensing potential, and a stronger strategic profile than many small biotech peers.

Xencor develops engineered antibody medicines and licenses its platform to drug partners. The appeal rests on a recognized antibody technology base, multiple shots on goal, and the possibility that future milestones and royalties become much more meaningful over time.

Zenas BioPharma is building immune-based treatments for autoimmune diseases, a large and growing area of healthcare. The appeal centers on pipeline progress and potential clinical differentiation, while recent stock strength shows how closely the market is tracking that upside.

Dentsply Sirona supplies dental equipment, software, implants, aligners, and everyday clinical products worldwide. Its broad reach and exposure to digital dentistry keep it relevant, while the central question is whether operational repair can restore growth and margins.

Xeris is building a stronger specialty pharma platform around Gvoke, Recorlev, and Keveyis. Revenue growth has remained well above sector norms, free cash flow has turned positive, and the company is moving closer to durable profitability.